Evotec AG today announced a strategic collaboration on microfluidics technology including induced pluripotent stem cell („iPSC“) differentiation with leading academic institutions in the UK and Italy to accelerate the discovery of novel drugs to treat kidney diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-joins-forces-with-academic-leaders-to-accelerate-drug-discovery-in-kidney-diseases-and-build-neplex-5510